Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Expected to Rise, Evercore ISI Analyst Says

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price target hoisted by research analysts at Evercore ISI from $30.00 to $35.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Evercore ISI’s price objective indicates a potential upside of 54.94% from the company’s current price.

Other analysts have also issued research reports about the company. Wedbush raised their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $34.60.

Kiniksa Pharmaceuticals Stock Performance

Shares of Kiniksa Pharmaceuticals stock opened at $22.59 on Wednesday. The firm has a fifty day simple moving average of $25.57 and a 200-day simple moving average of $22.42. Kiniksa Pharmaceuticals has a 1-year low of $14.12 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s revenue was up 67.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.20) EPS. Equities research analysts anticipate that Kiniksa Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at approximately $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares of the company’s stock, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 112,692 shares of company stock worth $2,950,315 over the last three months. Company insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. AlphaCentric Advisors LLC acquired a new position in Kiniksa Pharmaceuticals in the third quarter worth about $287,000. Harbor Capital Advisors Inc. bought a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $2,438,000. Rice Hall James & Associates LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 8.2% in the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock worth $16,234,000 after buying an additional 49,000 shares in the last quarter. AMI Asset Management Corp bought a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $1,281,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after buying an additional 3,076 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.